Using serial ctDNA monitoring, we found ctDNA detection to be strongly predictive of disease progression, OS, and PFS, outperforming PD-L1 CPS, which is the only current FDA-approved predictive and prognostic biomarker in R/M HNSCC. Here, CD274 is linked to head and neck squamous cell carcinoma.